Zoryve 0.3 % (Roflumilast FOAM) 0.3 %

Roflumilast works by inhibiting phosphodiesterase-4 (PDE4), an enzyme that degrades cyclic AMP (cAMP). By inhibiting PDE4, roflumilast increases intracellular cAMP levels, which leads to a reduction in the production of inflammatory cytokines. This mechanism helps to reduce inflammation and the symptoms associated with skin conditions like seborrheic dermatitis and psoriasis.

The usual dose of ZORYVE 0.3% Foam is determined by a healthcare provider based on the patient's condition and response to treatment. It is typically applied once daily to the affected areas. The prescriber will set the appropriate dosage and duration of treatment.

The safety of ZORYVE 0.3% Foam during pregnancy has not been established. It should not be used during pregnancy unless the benefits outweigh the risks. For breastfeeding women, it is advised to use the foam on the smallest area of the skin and for the shortest time needed. Avoid applying it directly to the nipple or areola to prevent contact with the baby.

To order ZORYVE 0.3% Foam from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. The team will ask you to confirm your trade or institutional credentials and will then provide pricing, availability, shipping details, and the necessary import paperwork.

ZORYVE 0.3% Foam is a steroid-free treatment option for seborrheic dermatitis, making it suitable for long-term use. Unlike topical steroids, it does not carry the risk of skin thinning or other steroid-related side effects. It is particularly effective for reducing inflammation and symptoms such as flaking and itching.

ZORYVE 0.3% Foam should be stored at room temperature, protected from light and moisture. Keep it out of reach of children. The foam is flammable, so avoid fire, flame, and smoking during and after application. Always follow the storage instructions provided with the medication.

ZORYVE 0.3% Foam is applied topically once daily to the affected areas. The foam should be gently massaged into the skin. Wash your hands with soap and water after applying the foam, unless you are treating areas on your hands. Avoid contact with the eyes, mouth, and vagina.

The most serious risks associated with ZORYVE 0.3% Foam include severe allergic reactions and liver function abnormalities. Patients with pre-existing liver conditions should be monitored closely. If you experience symptoms such as rash, itching, swelling, severe diarrhea, or signs of liver problems, seek medical attention immediately.

ZORYVE 0.3% Foam should not be used by individuals who are allergic to roflumilast or any of the ingredients in the foam. It is also not recommended for children under 9 years of age for the treatment of seborrheic dermatitis. Patients with moderate to severe liver impairment should use it with caution and under medical supervision.